Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA(Sipa via AP Images)
October 12, 2020 06:51 AM EDTUpdated 07:21 AM
Coronavirus

As­traZeneca gets a $500M an­ti­body con­tract, yet key ques­tions still loom for Trump's new fa­vorite treat­ment

Jason Mast

Editor

As Pres­i­dent Trump touts the sup­posed ‘mir­a­cle‘ ef­fects of Re­gen­eron’s an­ti­body treat­ments on Twit­ter and Fox News, the fed­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times